AptaTargets signed in May 2025 a licensing agreement with Merck for the clinical development and global commercialisation of ApTOLL, an aptamer with neuroprotective effect for the treatment of ischaem...
Read moreYouth entrepreneurship emerges as a natural response to a changing environment, where young people seek to transform ideas into real solutions and face social challenges with creativity, initiative an...
Read moreGENESIS Biomed closes 2025 as its best year ever, with strong growth compared to 2024: 506 projects (+26.5%) and 323 customers (+43.6%).
Read moreEn Albian, entienden que, para ofrecer la máxima excelencia exterior, deben evolucionar constantemente desde su interior. Por ello, han completado la ampliación y optimización de sus sedes en el Pa...
Read moreJosep Samitier: “It’s key to strengthen public-private collaboration and attract venture capital to promote emerging projects that will allow us to consolidate technological and productive capacit...
Read moreThe event brought together experts from hospitals, research organizations, industry and innovation ecosystems to co-create sustainable service models for the Paediatric Health Data Space (PHDS).
Read moreJoan Martí: “Corporate culture is a critical factor in M&A and partnership processes.”
Read moreGENESIS Biomed ha lanzado el programa GENESIS CEO Academy, una iniciativa formativa diseñada para preparar a los líderes del futuro en el ámbito de las ciencias de la vida. Este programa está orie...
Read moreACCIÓ’s Noves Oportunitats de Negoci calls for proposals provide Catalan companies with a supportive framework for analysing and structuring new growth opportunities.
Read more